IL6 and neoplasm: Indeed, Lu et al. indicated that combined IL-6 and PD-L1 blockade can effectively inhibit HCC growth in vivo, and a group treated with both IL-6 and PD-L1 exhibited smaller tumor volumes and longer survival times than a control group [65].